Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome

加强了Neurocrine的罕见病产品组合，推出了VYKAT™ XR，这是首个且唯一获批用于治疗普拉德-威利综合征中贪食症的药物。

Adds recently launched therapy with strong early adoption and meaningful commercial potential

增加了最近推出的治疗方案，该方案具有强烈的早期采用和有意义的商业潜力。

SAN DIEGO

圣地亚哥

,

，

May 18, 2026

2026年5月18日

/PRNewswire/ --

/PRNewswire/ --

Neurocrine Biosciences, Inc.

神经分泌生物科学公司

(Nasdaq:

（纳斯达克：

NBIX

NBIX

) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's first-in-class commercial portfolio alongside INGREZZA.

）今天宣布已完成对Soleno Therapeutics, Inc.的收购，进一步巩固了公司在内分泌学和罕见病领域的领导地位。此次收购将VYKAT™ XR（二氮嗪胆碱）片剂加入Neurocrine的首创商业化产品组合，与INGREZZA一同成为首个也是唯一获批用于治疗4岁及以上Prader-Willi综合征成人和儿童患者的多食症药物。

®

®

(valbenazine) and CRENESSITY

(valbenazine) 和 CRENESSITY

®

®

(crinecerfont).

（克里内塞方特）。

'Today marks an important advancement in Neurocrine's mission to deliver life-changing treatments for patients with significant unmet needs,' said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. 'We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community, and we look forward to working together to make VYKAT XR available to more patients and their families.'.

“今天标志着Neurocrine在为有重大未满足需求的患者提供改变生活的治疗方案这一使命上取得了重要进展，”Neurocrine Biosciences首席执行官凯尔·W·加诺博士表示。“我们欢迎Soleno的同事们加入Neurocrine，并与他们一样对普拉德-威利综合征群体怀有深切承诺。我们期待共同努力，让VYKAT XR惠及更多患者及其家庭。”

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15 that affects about 10,000 patients in the United States. The disease is characterized by neurological, behavioral, and metabolic dysfunction. Its defining feature is hyperphagia, a chronic, life-threatening condition marked by a persistent hunger that drives compulsive food-seeking behavior.

普拉德-威利综合征 (PWS) 是一种罕见的遗传性神经发育障碍，由15号染色体上的基因表达异常引起，在美国约影响10,000名患者。该疾病以神经系统、行为和代谢功能障碍为特征。其最显著的特点是过度食欲，这是一种慢性且危及生命的状况，表现为持续的饥饿感，驱使强迫性的觅食行为。

Individuals with PWS also commonly experience cognitive impairment and a range of psychiatric and behavioral challenges. Together, these symptoms can severely diminish quality of life for individuals with PWS and their families, with hyperphagia driving significant morbidity and mortality..

普拉德-威利综合征患者通常还会出现认知障碍以及一系列精神和行为方面的挑战。这些症状共同严重影响普拉德-威利综合征患者及其家人的生活质量，其中过度饥饿是导致显著发病和死亡的重要因素。

Neurocrine initially announced

神经内分泌公司最初宣布

the transaction

交易

– representing a total equity value of $2.9 billion – on April 6, 2026.

– 总股本价值为 29 亿美元 – 在 2026 年 4 月 6 日。

Transaction Details

交易明细

Neurocrine completed the cash tender offer through a subsidiary for all the outstanding shares of common stock of Soleno at a purchase price of $53.00 per share, without interest, subject to any applicable withholding taxes.

Neurocrine通过一家子公司完成了对Soleno所有已发行普通股的现金要约收购，收购价格为每股53.00美元，不计利息，并受任何适用的预扣税款的影响。

As of the tender offer expiration at one minute after 11:59 p.m. EDT on May 15, 2026, 46,356,114 shares of Soleno common stock were validly tendered and not validly withdrawn, representing approximately 88.9% of the total number of Soleno's issued and outstanding shares of common stock as of such date and time.

截至2026年5月15日东部时间晚上11点59分后一分钟的要约收购到期时，已有46,356,114股Soleno普通股被有效提交且未被有效撤回，约占该日期和时间Soleno已发行流通普通股总数的88.9%。

In accordance with the terms of the tender offer, all such shares have been accepted for payment..

根据要约条款，所有这些股份都已被接受付款。

Following its acceptance of the tendered shares, Neurocrine completed its acquisition of Soleno through the merger of a direct wholly owned subsidiary of Neurocrine with and into Soleno, pursuant to Section 251(h) of the Delaware General Corporation Law on May 18, 2026, with Soleno continuing as the surviving corporation and becoming a direct, wholly owned subsidiary of Neurocrine.

在接受所投标股份后，Neurocrine 通过其直接全资子公司与 Soleno 合并完成了对 Soleno 的收购。该合并依据《特拉华州普通公司法》第 251(h) 条于 2026 年 5 月 18 日完成，Soleno 继续作为存续公司，并成为 Neurocrine 的直接全资子公司。

All remaining shares of Soleno common stock that were not validly tendered in the tender offer were converted into the right to receive the same $53 per share in cash, without interest, subject to any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer.

所有在要约收购中未有效提交的Soleno普通股剩余股份均被转换为有权获得相同的每股53美元现金（无利息），并受任何适用的预扣税款影响，这与这些股份在要约收购中有效提交时应得的金额相同。

As of May 18, 2026, Soleno's common stock will no longer be listed or traded on the Nasdaq Capital Market..

截至2026年5月18日，Soleno的普通股将不再在纳斯达克资本市场上市或交易。

Advisors

顾问

Goldman Sachs & Co. LLC served as exclusive financial advisor, and Cooley LLP served as legal advisor to Neurocrine. Centerview Partners LLC and Guggenheim Securities, LLC served as financial advisors, and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal counsel to Soleno.

高盛有限责任公司担任Neurocrine的独家财务顾问，科利律师事务所担任其法律顾问。Centerview Partners有限责任公司和Guggenheim Securities有限责任公司担任Soleno的财务顾问，Wilson Sonsini Goodrich & Rosati专业公司担任其法律顾问。

About PWS

关于PWS

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families.

普拉德-威利综合征（PWS）是一种罕见的遗传性神经发育障碍，由15号染色体上的基因表达异常引起。美国普拉德-威利综合征协会估计，PWS在每15,000例活产婴儿中发生一例。PWS的定义性症状是贪食症，这是一种慢性且危及生命的状况，其特征是强烈的持续饥饿感，伴随对食物的强迫性关注、极强的进食驱动力、与食物相关的行为问题以及缺乏正常的饱腹感，这会严重降低PWS患者及其家庭的生活质量。

Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food-seeking behavior) and longer-term comorbidities such as diabetes, obesity, and cardiovascular disease..

过度饮食可导致显著的死亡率（例如，胃破裂、窒息、因觅食行为导致的意外死亡）以及长期的并发症，如糖尿病、肥胖和心血管疾病。

About INGREZZA® (valbenazine)

关于INGREZZA®（缬苯那嗪）

Please see

请参见

additional safety information

额外的安全信息

, full

，完整

Prescribing Information

处方信息

, including Boxed Warning, and

，包括加框警告，以及

Medication Guide

药物指南

.

。

About CRENESSITY® (crinecerfont)

关于CRENESSITY®（克里内塞方）

Please see

请参见

additional safety information

额外的安全信息

and full

并且充满

Prescribing Information

处方信息

.

。

About VYKAT XR

关于VYKAT XR

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

VYKAT XR 于2025年3月26日获得美国食品和药物管理局（FDA）批准，现已在美国上市，供患者使用。

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

VYKAT XR 适用于治疗 4 岁及以上患有普拉德-威利综合征 (PWS) 的成人和儿童患者的过度饥饿症。

INDICATION

适应症

VYKAT XR (diazoxide choline) extended-release tablets is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

VYKAT XR（二氮嗪胆碱）缓释片适用于治疗4岁及以上患有普拉德-威利综合征（PWS）的成人和儿童患者的过度饥饿症。

IMPORTANT SAFETY INFORMATION

重要的安全信息

Contraindications

禁忌症

Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.

对二氮嗪、VYKAT XR的其他成分或噻嗪类药物过敏的患者禁用VYKAT XR。

Warnings and Precautions

警告和注意事项

Hyperglycemia

高血糖

Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia..

高血糖，包括糖尿病酮症酸中毒，已有报道。在开始使用VYKAT XR之前，检测空腹血浆葡萄糖（FPG）和糖化血红蛋白（HbA1c）；对高血糖患者优化血糖控制。在治疗期间，定期监测空腹血糖（FPG或空腹血糖）和糖化血红蛋白（HbA1c）。对于有高血糖风险因素的患者，在治疗的最初几周内应更频繁地监测空腹血糖。

Risk of Fluid Overload

液体过载风险

Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.

据报道，包括与液体过量相关的严重反应在内的水肿已经发生。监测水肿或液体过量的体征或症状。VYKAT XR 尚未在心脏储备受损的患者中进行研究，因此在这些患者中应谨慎使用。

Adverse Reactions

不良反应

The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.

最常见的不良反应（发生率≥10%，且至少比安慰剂高2%）包括多毛症、水肿、高血糖和皮疹。

Please see the full

请参阅完整内容

Prescribing Information, including Medication Guide

处方信息，包括药物指南

.

。

About

关于

Neurocrine Biosciences

神经内分泌生物科学

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders.

Neurocrine Biosciences是一家领先的生物制药公司，拥有一个简单的使命：减轻有重大需求患者的痛苦。我们致力于为那些尚未得到充分关注的神经、精神、内分泌和免疫疾病患者发现并开发改变生活的治疗方法。

The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.

公司多样化的产品组合包括FDA批准的治疗药物，适应症涵盖迟发性运动障碍、亨廷顿病相关的舞蹈症、经典先天性肾上腺皮质增生症、普拉德-威利综合征患者的食欲亢进、子宫内膜异位症*和子宫肌瘤*，同时在我们的核心治疗领域中还有多款化合物处于中期至后期临床开发阶段的强大研发管线。

For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit .

三十多年来，我们运用自己对神经科学以及大脑和身体系统之间相互联系的独特见解来治疗复杂疾病。我们不懈地研发药物以减轻衰弱性疾病和病症带来的负担，因为您值得拥有勇敢的科学。欲了解更多信息，请访问。

neurocrine.com

neurocrine.com

, and follow the company on

，并关注公司动态

LinkedIn

领英

,

，

X

X

,

，

Facebook

Facebook

and

和

YouTube.

YouTube.

(

(

*in collaboration with AbbVie

*与AbbVie合作

)

)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. SOLENO is a registered trademark of Soleno Therapeutics, Inc. VYKAT is a trademark of Soleno Therapeutics, Inc.

神经内分泌、神经内分泌生物科学标志、你值得拥有勇敢的科学、INGREZZA 和 CRENESSITY 是 Neurocrine Biosciences, Inc. 的注册商标。SOLENO 是 Soleno Therapeutics, Inc. 的注册商标。VYKAT 是 Soleno Therapeutics, Inc. 的商标。

Forward-Looking Statements

前瞻性声明

This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Neurocrine, including statements regarding Neurocrine's acquisition of Soleno, the prospective benefits of the acquisition; Neurocrine's strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to its future financial results and growth potential, anticipated product portfolio, and development programs; the estimated occurrence of PWS; the estimated U.S. population of PWS patients; and other statements that are not historical facts.

本通讯包含关于未来事件和Neurocrine未来业绩的前瞻性声明，涉及风险和不确定性，包括关于Neurocrine收购Soleno的声明、此次收购的预期收益；Neurocrine的战略、计划、目标、期望（财务或其他方面）及其对未来财务结果和增长潜力、预期产品组合和开发项目的意图；PWS的估计发生率；美国PWS患者的估计人口；以及其他非历史事实的声明。

The forward-looking statements contained in this communication are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. These statements may contain words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'future,' 'intend,' 'may,' 'opportunity,' 'plan,' 'potential,' 'project,' 'seek,' 'should,' 'strategy,' 'will,' 'would' or other similar words and expressions indicating future results.

本通讯中包含的前瞻性陈述基于当前的预期和假设，这些预期和假设受到风险和不确定性的约束，可能导致实际结果与前瞻性陈述产生重大差异。这些陈述可能包含诸如“预期”、“相信”、“可能”、“估计”、“预计”、“未来”、“意图”、“或许”、“机会”、“计划”、“潜在”、“预计”、“寻求”、“应该”、“策略”、“将”、“会”等词语或其他类似的词语和表达，表明未来的结果。

Risks that may cause these forward-looking statements to be inaccurate include, without limitation: risks related to Neurocrine's ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that Neurocrine will not be able to integrate Soleno successfully or that such integration may be more difficult, time-consuming or costly than expected; disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with employees, customers, sup.

可能导致这些前瞻性陈述不准确的风险包括但不限于：与Neurocrine实现收购预期收益能力相关的风险，包括可能无法实现收购的预期收益或无法在预期时间内实现，以及Neurocrine可能无法成功整合Soleno，或此类整合可能比预期更困难、耗时或成本更高；因收购带来的业务中断，导致难以照常开展业务或维持与员工、客户、供应商的关系。

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved.

© 2026 Neurocrine Biosciences, Inc. 保留所有权利。

SOURCE Neurocrine Biosciences, Inc.

来源：Neurocrine Biosciences, Inc.

21

21

%

%

more press release views with

更多新闻发布观点

Request a Demo

请求演示